Serum Soluble Suppression of Tumorigenicity-2 Levels Predict Cardiovascular Events in Patients Undergoing Incident Peritoneal Dialysis: A Prospective Cohort Study
Kidney and Blood Pressure Research · 2024
DOI: 10.1159/000540657 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Kidney and Blood Pressure Research, 2024. Verfasst von Yunyun Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Institute of Nephrology, West China Hospital of Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Interleukin-1 Receptor-Like 1 Protein, Peritoneal Dialysis, Cardiovascular Diseases. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Biomarkers are urgently required to identify peritoneal dialysis (PD) patients at risk of cardiovascular (CV) events. This study aimed to investigate the predictive value of soluble suppression of tumorigenicity-2 (sST2) for CV events in patients undergoing incident PD.
Methods
In this prospective cohort study, incident PD patients were enrolled. Blood samples to measure sST2 levels were obtained before PD catheter implantation. The patients underwent a standard peritoneal equilibration test (PET) after initiation of PD for 4–6 weeks. The sST2 levels in both serum and dialysate were determined using enzyme-linked immunosorbent assay. CV events were recorded during the follow-up period.
Results
A total of 137 patients were enrolled. During the follow-up period of 17.3 months, 49 (35.76%) patients experienced CV events. When patients were dichotomized based on the median values and the calculated cutoff values of sST2, the higher sST2 group had 2.980- and 3.048-fold increased risks of CV events, respectively, when compared with the lower sST2 group. Moreover, the prognostic value of sST2 remained significant as a continuous variable (per 1 standard deviation increase, hazard ratio [HR] = 1.037, 95% confidence interval [CI] 1.010–1.066, p = 0.008). N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were found to indicate a higher risk only when dichotomized based on the calculated cutoff values. Furthermore, serum sST2 and NT-proBNP levels simultaneously above the calculated cutoff values were associated with a higher risk of CV events (HR = 3.398, 95% CI 1.813–6.367, p < 0.001).
Conclusion
Baseline serum sST2 level is an independent predictor of the risk of CV events in patients receiving incident PD, and in combination with NT-proBNP level, it can provide a more accurate predictive value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Institute of Nephrology, West China Hospital of Sichuan University, Chengdu, China.
- Department of Nephrology, The Second People's Hospital of Yibin, Yibin, China.
- The Hospital of Chongqing University of Posts and Telecommunications, Chongqing, China.
- Department of Nephrology, The Third People's Hospital of Chengdu, Chengdu, China.
- Department of Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China.
Zitieren
APA
Zhang, Y., Xu, Q., Wu, X., Pu, L., Zang, Z., Xia, X., Ma, N., & Li, Z. (2024). Serum Soluble Suppression of Tumorigenicity-2 Levels Predict Cardiovascular Events in Patients Undergoing Incident Peritoneal Dialysis: A Prospective Cohort Study. Kidney and Blood Pressure Research. https://doi.org/10.1159/000540657
Vancouver
Zhang Y, Xu Q, Wu X, Pu L, Zang Z, Xia X, et al. Serum Soluble Suppression of Tumorigenicity-2 Levels Predict Cardiovascular Events in Patients Undergoing Incident Peritoneal Dialysis: A Prospective Cohort Study. Kidney and Blood Pressure Research. 2024. doi:10.1159/000540657
BibTeX
@article{Zhang2024,
author = {Zhang, Yunyun and Xu, Qijiang and Wu, Xiaofang and Pu, Li and Zang, Zhiyun and Xia, Xiaoxiao and Ma, Niya and Li, Zi},
title = {Serum Soluble Suppression of Tumorigenicity-2 Levels Predict Cardiovascular Events in Patients Undergoing Incident Peritoneal Dialysis: A Prospective Cohort Study},
journal = {Kidney and Blood Pressure Research},
year = {2024},
doi = {10.1159/000540657}
}
EUVIMED